KLCM Advisors Inc. Sells 263,766 Shares of Kenvue Inc. $KVUE

Key Points

• KLCM Advisors Inc. has reduced its stake in Kenvue Inc. (NYSE:KVUE) by 31.8%, selling 263,766 shares, and now holds 565,905 shares valued at approximately $13.57 million.
• Several analysts have lowered their price targets for Kenvue, with Barclays and Royal Bank of Canada both setting targets at $22.00, indicating a cautious outlook on the stock.
• Kenvue announced a quarterly dividend increase to $0.2075 per share, representing an annual yield of 3.8%, despite a 4.0% decrease in year-over-year revenue.

KLCM Advisors Inc. lessened its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 31.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 565,905 shares of the company's stock after selling 263,766 shares during the period. Kenvue comprises about 1.6% of KLCM Advisors Inc.'s portfolio, making the stock its 22nd largest holding. KLCM Advisors Inc.'s holdings in Kenvue were worth $13,570,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after buying an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Kenvue by 4.9% during the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after buying an additional 10,600,682 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Kenvue by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company's stock worth $613,882,000 after buying an additional 633,461 shares during the last quarter. Boston Partners lifted its stake in shares of Kenvue by 7.4% during the 1st quarter. Boston Partners now owns 25,346,453 shares of the company's stock worth $606,920,000 after buying an additional 1,750,490 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Kenvue by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company's stock worth $597,395,000 after buying an additional 2,597,920 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE traded up $0.3170 during mid-day trading on Tuesday, reaching $21.4170. The stock had a trading volume of 3,728,600 shares, compared to its average volume of 17,480,318. The stock has a 50-day simple moving average of $21.54 and a two-hundred day simple moving average of $22.43. The stock has a market capitalization of $41.10 billion, a PE ratio of 29.02, a P/E/G ratio of 3.05 and a beta of 0.83. Kenvue Inc. has a 12 month low of $19.75 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th will be issued a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is presently 112.16%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KVUE shares. Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Canaccord Genuity Group cut their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Barclays cut their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Finally, Bank of America cut their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.